Sidoti Csr Issues Pessimistic Estimate for PHIO Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Equities researchers at Sidoti Csr decreased their FY2026 earnings estimates for Phio Pharmaceuticals in a report released on Monday, November 17th. Sidoti Csr analyst A. Hantman now expects that the company will post earnings per share of ($1.06) for the year, down from their previous forecast of ($1.05). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ FY2027 earnings at ($0.79) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Thursday, November 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01.

A number of other equities research analysts have also weighed in on PHIO. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Phio Pharmaceuticals in a report on Friday, August 15th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.

Phio Pharmaceuticals Price Performance

Phio Pharmaceuticals stock traded down $0.00 during midday trading on Thursday, hitting $1.25. 68,400 shares of the stock were exchanged, compared to its average volume of 3,681,042. Phio Pharmaceuticals has a 1 year low of $0.97 and a 1 year high of $9.79. The firm has a market cap of $7.15 million, a P/E ratio of -0.38 and a beta of 0.97. The company has a 50 day moving average price of $2.03 and a two-hundred day moving average price of $2.14.

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,694 shares of the company’s stock after acquiring an additional 16,108 shares during the period. Geode Capital Management LLC owned about 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent quarter. 57.31% of the stock is owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.